Special reference targets pharmacists

Share this article:
Monthly Prescribing Reference is targeting pharmacists with a new edition aimed at providing them a counter-top quick-reference.

The Haymarket title will launch a quarterly edition in January 2007, featuring original content and going out to pharmacists in charge at 59,000 stores nationwide—chains and pharmacies alike—based on the National Council of Prescription Drug Plans list.

“There's a need in the marketplace for this type of product,” said publisher Jim Pantaleo. “Pharmacists are the drug information experts. They go to school for six years to get their PharmDs. Our whole staff is made up of PharmDs, and throughout our 20-year history pharmacists have been subscribing out of their own pockets.”

Haymarket conducted a survey of MPR readers who are pharmacists and found strong demand for a special edition.

Existing reference books for pharmacists, like Wolters Kluwer Health's Facts & Comparisons and US PDI, are too unwieldy and difficult to update, said editorial director Jim Burke, RPh.
“They sit back behind the desk and collect dust,” said Burke.

Many pharmacies, he added, are not online, and most drug reference software is little use
beyond checking for drug interactions.

Few pharmacists, he said, have portable devices, “And we have to spend a lot of our day in the aisle.”

MPR, a slender volume updated quarterly, hopes to cash in on that need by providing them a quick and easy reference that will fit easily into the pocket of a lab coat.

With the Medicare prescription drug benefit magnifying the role of the pharmacist, Pantaleo said prospective advertisers are showing interest in the title, even if they're not biting quite yet.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...